ATE366581T1 - Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen - Google Patents
Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungenInfo
- Publication number
- ATE366581T1 ATE366581T1 AT01935897T AT01935897T ATE366581T1 AT E366581 T1 ATE366581 T1 AT E366581T1 AT 01935897 T AT01935897 T AT 01935897T AT 01935897 T AT01935897 T AT 01935897T AT E366581 T1 ATE366581 T1 AT E366581T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- patient
- neurodegenerative
- cells
- apoptotic
- Prior art date
Links
- 230000001640 apoptogenic effect Effects 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2309424 CA2309424A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366581T1 true ATE366581T1 (de) | 2007-08-15 |
Family
ID=4166243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01935897T ATE366581T1 (de) | 2000-05-25 | 2001-05-25 | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7132285B2 (enExample) |
| EP (1) | EP1289535B1 (enExample) |
| JP (1) | JP2003534282A (enExample) |
| AT (1) | ATE366581T1 (enExample) |
| AU (1) | AU2001261987A1 (enExample) |
| CA (1) | CA2309424A1 (enExample) |
| DE (1) | DE60129322T2 (enExample) |
| DK (1) | DK1289535T3 (enExample) |
| ES (1) | ES2290134T3 (enExample) |
| PT (1) | PT1289535E (enExample) |
| TW (1) | TWI239843B (enExample) |
| WO (1) | WO2001089537A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309518A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| TWI281407B (en) * | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| CA2333494A1 (en) * | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| EP1429727A1 (en) * | 2001-09-18 | 2004-06-23 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| US20060008517A1 (en) * | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| US6696092B2 (en) * | 1992-02-07 | 2004-02-24 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
| ATE219953T1 (de) | 1992-02-07 | 2002-07-15 | Vasogen Inc | Verfahren zur erhöhung den stickoxidkonzentration im blut |
| PT1146885E (pt) * | 1999-01-12 | 2003-10-31 | Vasogen Ireland Ltd | Pre-condicionamento contra a morte celular |
| CA2271190A1 (en) * | 1999-05-06 | 2000-11-06 | Vasogen Ireland Limited | Improved method for treating mammals with modified mammalian blood |
| CN1187507C (zh) | 2000-03-07 | 2005-02-02 | E·F·P·地板制品有限公司 | 嵌板 |
| CA2309417A1 (en) | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| CA2309518A1 (en) | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| US7122208B2 (en) * | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
| EP1469733A4 (en) | 2001-11-29 | 2008-07-23 | Therakos Inc | METHOD FOR PRE-TREATING A PATIENT WITH EXTRACORPORAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS |
| US7255880B2 (en) * | 2003-04-03 | 2007-08-14 | Vasogen Ireland Limited | Treatment of endothelin-related disorders |
-
2000
- 2000-05-25 CA CA 2309424 patent/CA2309424A1/en not_active Abandoned
-
2001
- 2001-05-25 WO PCT/CA2001/000759 patent/WO2001089537A2/en not_active Ceased
- 2001-05-25 DK DK01935897T patent/DK1289535T3/da active
- 2001-05-25 PT PT01935897T patent/PT1289535E/pt unknown
- 2001-05-25 AT AT01935897T patent/ATE366581T1/de not_active IP Right Cessation
- 2001-05-25 ES ES01935897T patent/ES2290134T3/es not_active Expired - Lifetime
- 2001-05-25 AU AU2001261987A patent/AU2001261987A1/en not_active Abandoned
- 2001-05-25 DE DE2001629322 patent/DE60129322T2/de not_active Expired - Fee Related
- 2001-05-25 US US09/871,146 patent/US7132285B2/en not_active Expired - Fee Related
- 2001-05-25 EP EP20010935897 patent/EP1289535B1/en not_active Expired - Lifetime
- 2001-05-25 JP JP2001585781A patent/JP2003534282A/ja not_active Withdrawn
- 2001-06-01 TW TW90113346A patent/TWI239843B/zh not_active IP Right Cessation
-
2006
- 2006-10-17 US US11/583,986 patent/US20070087010A1/en not_active Abandoned
-
2007
- 2007-10-29 US US11/927,094 patent/US20080131416A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1289535B1 (en) | 2007-07-11 |
| DE60129322D1 (de) | 2007-08-23 |
| DE60129322T2 (de) | 2008-03-13 |
| US20020044924A1 (en) | 2002-04-18 |
| US20070087010A1 (en) | 2007-04-19 |
| HK1055080A1 (en) | 2003-12-24 |
| EP1289535A2 (en) | 2003-03-12 |
| US20080131416A1 (en) | 2008-06-05 |
| ES2290134T3 (es) | 2008-02-16 |
| PT1289535E (pt) | 2007-10-19 |
| TWI239843B (en) | 2005-09-21 |
| AU2001261987A1 (en) | 2001-12-03 |
| CA2309424A1 (en) | 2001-11-25 |
| WO2001089537A3 (en) | 2002-08-01 |
| WO2001089537A2 (en) | 2001-11-29 |
| DK1289535T3 (da) | 2007-11-05 |
| JP2003534282A (ja) | 2003-11-18 |
| US7132285B2 (en) | 2006-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE237339T1 (de) | Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| ES2052733T3 (es) | Dispositivo electroterapeutico de baja frecuencia. | |
| ATE162399T1 (de) | Terfanadin metaboliten und deren optisch reine isomere zur behandlung von allergischen krankheiten | |
| EP1658853A4 (en) | MEDIUM FOR INTERNAL ADMINISTRATION FOR DISEASES OF NERVES IN THE HEAD WITH MESENCYCLES AS AN ACTIVE SUBSTANCE | |
| ATE366581T1 (de) | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen | |
| ATE311191T1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
| Gileva et al. | Hirudotherapy | |
| PT2111868E (pt) | Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos | |
| DE4394931T1 (de) | Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen | |
| ATE198550T1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| BR0307041A (pt) | Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes | |
| DE3685853D1 (de) | Mittel zur behandlung von knochenkrankheiten. | |
| ATE289805T1 (de) | Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren | |
| DE69928521D1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
| ATE281157T1 (de) | Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE373482T1 (de) | Pharmazeutische zusammensetzung zur lokalen behandlung von hauterkrankungen und hautwunden | |
| RU2090143C1 (ru) | Способ лечения сирингомиелии | |
| RU2013092C1 (ru) | Способ лечения отека мозга при туберкулезном менингоэнцефалите | |
| DE602004025040D1 (de) | Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid | |
| SU591196A1 (ru) | Способ лечени больных с последстви ми сосудистых заболеваний и травматических повреждений головного мозга | |
| HUP9701606A2 (hu) | Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására | |
| Jajoo et al. | Management Of Non-Healing Ulcer Associated With Atherosclerosis Through Jalukaavcharan And Yashad Bhasma Application-Case Report. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |